Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 20
Filtrer
3.
Int Wound J ; 20(3): 678-686, 2023 Mar.
Article de Anglais | MEDLINE | ID: mdl-35945908

RÉSUMÉ

Receptor for Advanced Glycated End-products (RAGE) is highly expressed in diabetes and impairs wound healing. We proposed that administering an antibody that blocks RAGE will hasten the healing of dorsal wounds in diabetic pigs compared with a non-immune IgG. Two purpose-bred diabetic (D) Yucatan minipigs (Sinclair, Auxvasse MO) each underwent 12 2 × 2 cm full thickness dorsal wounds: four wounds received decellularized porcine skin patches (Xylyx Bio, Bklyn NY): four anti-RAGE Ab (CR-3) infused patches, four saline infused patches and four wounds were left open. One pig received anti-RAGE Ab (CR-3) 1 mg/kg IM q 10 days and other received non-immune IgG. Wounds were measured at 2 and 4 weeks followed by euthanasia and wound harvesting. At 2 weeks few of the patches appeared to be incorporated into the wound. By 4 weeks all patches in pigs treated systemically with CR-3 were detached and the wounds almost healed. For all 24 wounds for both pigs regardless of presence of patch or type of patch, the average IgG treated pig wound size at 4 weeks was 69.2 ± 14.6% of initial size and the average CR-3 treated pig wound size was 40.9 ± 11.3% of initial size (P = 0.0002). Quantitative immunohistology showed greater staining for collagen in the CR-3 treated wounds compared with IgG treated. Staining was positive for RAGE, Mac, and IL-6 in the IgG treated wounds and negative in the CR-3 treated wounds. From these pilot experiments, we conclude that a RAGE blocking antibody given parenterally improved wound healing in a diabetic pig while patches were not effective.


Sujet(s)
Diabète , Cicatrisation de plaie , Suidae , Animaux , Porc miniature , Collagène , Immunoglobuline G
4.
Pediatr Dermatol ; 39(2): 322-323, 2022 Mar.
Article de Anglais | MEDLINE | ID: mdl-35028971

RÉSUMÉ

Pigmented epithelioid melanocytoma (PEM) is an intermediate-grade melanocytic tumor with considerable histologic overlap with other melanocytic neoplasms such as epithelioid blue nevus (EBN), which is associated with the neoplastic syndrome Carney complex (CC). Next-generation sequencing is a valuable tool for identifying the primary drivers of melanocytic neoplasms and differentiating them from one another. While germline variants in the protein kinase cAMP-dependent regulatory type 1 alpha (PRKAR1A) gene have been associated with EBN and CC, fusions in protein kinase C-alpha (PRKCA) have been shown as sporadic drivers of PEM. Herein, we report the diagnosis and workup of a case of pigmented epithelioid melanocytoma with a novel protein kinase C-beta (PRKCB) fusion.


Sujet(s)
Naevus bleu , Tumeurs cutanées , Humains , Naevus bleu/diagnostic , Naevus bleu/génétique , Naevus bleu/anatomopathologie , Protein kinase C beta , Tumeurs cutanées/diagnostic , Tumeurs cutanées/génétique , Tumeurs cutanées/chirurgie , Antigène CD63
8.
Am J Dermatopathol ; 43(1): 57-59, 2021 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-32568833

RÉSUMÉ

ABSTRACT: Papillary digital adenocarcinoma (PDA) is a rare eccrine tumor that is most often found on the digits. Few case reports have described PDAs located on atypical sites. It is now accepted that PDAs cannot be distinguished from benign adenomas based on histological features, and it is recommended to excise all of these lesions. Even with excision, recurrence and metastasis rates are high. Only limited genomic analyses have been performed to date, and no driver mutations have been identified. We report a case of a 63-year-old woman with a PDA on the right forearm. Biopsy showed moderate cytologic atypia and mitotic figures. Next-generation DNA sequencing of the tumor showed a BRAFV600E mutation and high tumor mutational burden (5.51 mutations/Mb). This mutation is known for its response to small molecular inhibitors of BRAF and Mitogen-activated protein kinase kinase. Such therapy may be a consideration should our patient develop recurrent unresectable disease.


Sujet(s)
Adénocarcinome papillaire/génétique , Marqueurs biologiques tumoraux/génétique , Mutation , Protéines proto-oncogènes B-raf/génétique , Tumeurs des glandes sudoripares/génétique , Adénocarcinome papillaire/anatomopathologie , Adénocarcinome papillaire/chirurgie , Analyse de mutations d'ADN , Femelle , Avant-bras , Séquençage nucléotidique à haut débit , Humains , Adulte d'âge moyen , Tumeurs des glandes sudoripares/anatomopathologie , Tumeurs des glandes sudoripares/chirurgie
9.
Am J Dermatopathol ; 43(8): 554-555, 2021 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-33055537

RÉSUMÉ

ABSTRACT: "Severe acute respiratory syndrome coronavirus-2" (SARS-CoV-2) infection has variable described dermatologic manifestations. "COVID (coronavirus disease) toes" became a hallmark of the disease in young and largely asymptomatic patients, who may have negative test results for SARS-CoV-2. Pernio (chilblains)-like lesions are seen mostly in infected pediatric patients and are purple painful, frequently bilateral, ill-defined plaques with prominent inflammation on histological examination. In contrast to pernio-like presentation in children, critically ill adult patients with SARS-CoV-2 develop "purple" digits that may be sharply demarcated and may demonstrate asymmetric areas of ischemia. These 2 contrasting entities are sometimes grouped together as "COVID toes" due to some similarities in clinical appearance and presentation. Here, we summarize histopathologic examination from an autopsy, including the cutaneous lesions from the affected and normal contralateral toes and correlate them with systemic findings. In contrast to pernio-like lesions, the skin of the affected necrotic toes contained thrombi in vessels without prominent inflammation, suggestive of an embolic event. This is further supported by the clinical history of and autopsy findings of popliteal artery thrombus and multiple subsegmental pulmonary emboli. Our findings suggest that critically ill patients with SARS-CoV-2 have different pathological processes affecting skin at peripheral sites (ie, fingers, toes, ears, and nose), which may be due to thromboembolic events. The skin is a mirror of the body and skin pathology may shed light into overall pathogenesis of systemic illness and processes.


Sujet(s)
COVID-19/complications , COVID-19/anatomopathologie , Thrombose/virologie , Orteils/anatomopathologie , Autopsie , Humains , Mâle , Adulte d'âge moyen , SARS-CoV-2 , Orteils/vascularisation
11.
J Immunother Cancer ; 8(2)2020 11.
Article de Anglais | MEDLINE | ID: mdl-33203666

RÉSUMÉ

Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin with high rates of local recurrence and distant metastases despite treatment with traditional cytotoxic chemotherapies. The recent advances in immunotherapy, including the use of immune checkpoint blockade (ICB) has revolutionized treatment for this disease and resulted in durable responses for some patients. However, many patients, due to underlying conditions, have been insufficiently evaluated for potential use of immunotherapy. Here we present a case of ICB treatment with Programmed cell death protein 1 (PD-1) inhibition in a patient with underlying interstitial lung disease (ILD) and a new diagnosis of MCC. Through a multidisciplinary approach, we were able to maintain close monitoring with serial clinical and radiographical follow-up. The patient achieved a complete response though unrelated medical issues resulting in a treatment hold. At the last follow-up, the patient continued to experience a durable response without evidence of recurrence. This case describes the use of pembrolizumab, a PD-1 inhibitor, for the treatment of MCC in a patient with underlying ILD. The use of active surveillance with a multidisciplinary approach resulted in successful treatment of MCC without exacerbation of the underlying ILD.


Sujet(s)
Carcinome à cellules de Merkel/étiologie , Immunothérapie/méthodes , Pneumopathies interstitielles/complications , Sujet âgé , Carcinome à cellules de Merkel/anatomopathologie , Humains , Pneumopathies interstitielles/anatomopathologie , Mâle
12.
FASEB J ; 34(9): 13022-13032, 2020 09.
Article de Anglais | MEDLINE | ID: mdl-32776588

RÉSUMÉ

Currently, there is no sensitive molecular test for identifying transformation-prone actinic keratoses (AKs) and aggressive squamous cell carcinoma (SCC) subtypes. Biomarker-based molecular testing represents a promising tool for risk stratifying these lesions. We evaluated the utility of a panel of ultraviolet (UV) radiation-biomarker genes in distinguishing between benign and transformation-prone AKs and SCCs. The expression of the UV-biomarker genes in 31 SCC and normal skin (NS) pairs and 10 AK/NS pairs was quantified using the NanoString nCounter system. Biomarker testing models were built using logistic regression models with leave-one-out cross validation in the training set. The best model to classify AKs versus SCCs (area under curve (AUC) 0.814, precision score 0.833, recall 0.714) was constructed using a top-ranked set of 13 UV-biomarker genes. Another model based on a 15-gene panel was developed to differentiate histologically concerning from less concerning SCCs (AUC 1, precision score 1, recall 0.714). Finally, 12 of the UV-biomarker genes were differentially expressed between AKs and SCCs, while 10 genes were uniquely expressed in the more concerning SCCs. UV-biomarker gene subsets demonstrate dynamic utility as molecular tools to classify and risk stratify AK and SCC lesions, which will complement histopathologic diagnosis to guide treatment of high-risk patients.


Sujet(s)
Carcinome épidermoïde/génétique , Kératose actinique/génétique , Tumeurs cutanées/génétique , Peau/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Évolution de la maladie , Femelle , Marqueurs génétiques , Humains , Mâle , Adulte d'âge moyen , Appréciation des risques , Rayons ultraviolets/effets indésirables
13.
Clin Neuropathol ; 39(5): 232-237, 2020.
Article de Anglais | MEDLINE | ID: mdl-32383640

RÉSUMÉ

In this paper we report a case of the rare entity epithelial sheath neuroma (ESN). A 66-year-old white female presented with a 1-month history of pruritic, raised, erythematous skin lesion on her upper back. The clinical impression initially led to a differential diagnosis that included lymphoma or inflamed sebaceous cyst. The patient had past medical history significant for squamous cell carcinoma of skin of the left calf status post Mohs surgery 9 years prior to presentation and inflamed seborrheic keratosis of the shoulder 3 years prior to presentation. She had no history of surgery or trauma at the area of concern for this presentation. A punch biopsy obtained to characterize the lesion showed dermal fibrosis and proliferation of nerves throughout the dermis without significant atypia, consistent with the diagnosis of ESN. The histologic differential diagnosis of ESN is presented here, and we discuss its most likely pathogenesis. This diagnosis is important for the clinician to keep in mind as excision appears to be curative, and it can easily be mistaken for many other entities.


Sujet(s)
Névrome/anatomopathologie , Tumeurs cutanées/anatomopathologie , Sujet âgé , Carcinome épidermoïde/anatomopathologie , Femelle , Humains , Seconde tumeur primitive/anatomopathologie
14.
J Drugs Dermatol ; 19(2): 205-206, 2020 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-32155019

RÉSUMÉ

Here we report a case of linear porokeratosis with recurrent malignant degeneration to squamous cell carcinoma (SCC) recurring six years after excision of initial SCC. A 79-year-old woman presented with a friable tumor located within a longstanding lesion on her posterior thigh. Six years prior, she was diagnosed with SCC arising within the same lesion, which had been surgically excised with negative margins. Physical examination revealed a 3.5 x 2.7 cm friable tumor on the left proximal posterior thigh. The tumor was located within a hyperpigmented and erythematous scaly linear plaque within a line of Blaschko, extending from the left buttock to the left distal posterior thigh. Two 4 mm punch biopsies were performed: one of the erythematous plaque on the left buttock and one from the friable tumor on the left posteromedial thigh. Histology from the left buttock revealed a cornoid lamella consistent with porokeratosis and the left posteromedial thigh revealed SCC. The patient underwent Mohs micrographic surgery with negative margins, followed by a linear repair. Porokeratosis is a disorder of epidermal keratinization that has been associated with malignant degeneration, although such cases are rare. The risk of recurrence of SCC arising within a porokeratosis is unknown. This case emphasizes the importance of ongoing monitoring for malignant degeneration within these lesions. J Drugs Dermatol. 2020;19(2)205-206. doi:10.36849/JDD.2020.4640


Sujet(s)
Carcinome épidermoïde/diagnostic , Récidive tumorale locale/diagnostic , Porokératose/diagnostic , Tumeurs cutanées/diagnostic , Sujet âgé , Carcinome épidermoïde/chirurgie , Diagnostic différentiel , Femelle , Humains , Chirurgie de Mohs , Récidive tumorale locale/chirurgie , Porokératose/chirurgie , Tumeurs cutanées/chirurgie , Cuisse
15.
Pediatr Dermatol ; 37(1): 78-85, 2020 Jan.
Article de Anglais | MEDLINE | ID: mdl-31631401

RÉSUMÉ

BACKGROUND/OBJECTIVE: The pathogenesis of infantile hemangiomas (IH), PHACE, and LUMBAR syndromes remains unknown. We aim to describe histopathologic features of midline anomalies associated with IH, including patients with PHACE and LUMBAR syndromes. METHODS: A multicenter retrospective chart review was performed to identify patients with IH, PHACE, and LUMBAR syndrome with histopathologic specimens from sternal or midline anomalies. A total of 18 midline lesions from 13 patients were included. Out of 18, 14 midline lesions underwent both histopathologic and clinical review. Three hamartoma-like chin plaques and one supraumbilical raphe underwent only clinical review. RESULTS: All 13 patients had midline lesions and IH. Histopathologic diagnoses were as follows: rhabdomyomatous mesenchymal hamartoma (3), folliculosebaceous cystic hamartoma (1), fibroepithelial polyp (1), verrucous epidermal hyperplasia with vascular proliferation and fibroplasia (1), congenital midline cervical cleft (1), pericardium with fibrosis (1), fibrous components with increased collagen (1), atrophic skin/membrane (3), angiolipomatous mass with neural components (1), and lipomatous mass (1). Due to the retrospective nature of this study, it was not possible to obtain pathology slides for all midline lesions that had previously been biopsied or resected. We show clinically and histopathologically a new association between PHACE syndrome and rhabdomyomatous mesenchymal hamartoma (RMH), in addition to demonstrating the association between PHACE syndrome and chin hamartomas. We also display histopathologic findings seen in midline lesions resected from LUMBAR patients. CONCLUSION: Rhabdomyomatous mesenchymal hamartoma is thought to be related to aberrations of mesenchymal cells during development; therefore, this may provide clues to the pathogenesis of IH and related syndromes.


Sujet(s)
Coarctation aortique/anatomopathologie , Malformations/anatomopathologie , Malformations oculaires/anatomopathologie , Hamartomes/anatomopathologie , Hémangiome/anatomopathologie , Syndromes neurocutanés/anatomopathologie , Tumeurs cutanées/anatomopathologie , Malformations multiples , Femelle , Humains , Nourrisson , Mâle , Malformations du système nerveux/anatomopathologie , Études rétrospectives , Malformations cutanées/anatomopathologie , Syndrome
16.
J Cutan Pathol ; 47(1): 47-51, 2020 Jan.
Article de Anglais | MEDLINE | ID: mdl-31381162

RÉSUMÉ

Cutaneous metastases from hepatocellular carcinoma (HCC) are extremely rare and can represent a sign of an underlying malignancy or relapse/progression from an existing tumor. We report a case of a cutaneous metastasis arising in a patient with metastatic HCC following orthotopic liver transplantation. Diagnosis is a multistep process as cutaneous HCC metastases must be differentiated from primary cutaneous malignancies as well as other cutaneous metastases. Making this even more challenging, HCC metastases have heterogeneous clinical and histologic appearances. Therefore, the use of immunohistochemical stains, including hepatocyte paraffin-1, arginase-1, and glypican-3, and correlation with the clinical context are essential for a correct diagnosis.


Sujet(s)
Carcinome hépatocellulaire , Tumeurs de la face , Tumeurs du foie , Transplantation hépatique , Protéines tumorales/métabolisme , Tumeurs cutanées , Carcinome hépatocellulaire/métabolisme , Carcinome hépatocellulaire/anatomopathologie , Tumeurs de la face/métabolisme , Tumeurs de la face/anatomopathologie , Tumeurs de la face/secondaire , Fibrose/chirurgie , Humains , Tumeurs du foie/métabolisme , Tumeurs du foie/anatomopathologie , Mâle , Adulte d'âge moyen , Métastase tumorale , Tumeurs cutanées/métabolisme , Tumeurs cutanées/anatomopathologie , Tumeurs cutanées/secondaire
17.
J Med Case Rep ; 13(1): 169, 2019 May 30.
Article de Anglais | MEDLINE | ID: mdl-31142349

RÉSUMÉ

BACKGROUND: Pleomorphic dermal sarcoma is the cutaneous variant of undifferentiated pleomorphic sarcoma. It is a rare malignancy of unclear histogenesis; it is a diagnosis of exclusion that requires extensive use of immunohistochemistry to rule out other malignancies. Pleomorphic dermal sarcoma typically presents as a solitary tumor in sun-exposed areas and may have unpredictable clinical behavior, with some tumors associated with metastasis and death. CASE PRESENTATION: We present an unusual case of multifocal pleomorphic dermal sarcoma arising in the areas of alpha-1-antitrypsin deficiency panniculitis in a lung transplant patient. Our patient was a 58-year-old white woman whose initial presentation was consistent with alpha-1-antitrypsin deficiency panniculitis. She then developed extensive multifocal, bleeding, and ulcerated nodules in the areas of the panniculitis. A skin biopsy was consistent with a diagnosis of pleomorphic dermal sarcoma. Her immunosuppressive regimen was decreased, and she was treated with liposomal doxorubicin 40 mg/m2 every 3 weeks with some initial improvement in the size of her tumors. However, soon after beginning therapy, she developed pneumonia and septic shock and ultimately died from multi-organ failure. CONCLUSIONS: We hypothesize that chronic, multifocal inflammation in the skin in the setting of immunosuppression led to simultaneous, malignant transformation in numerous skin lesions. We discuss the challenges of diagnosing pleomorphic dermal sarcoma, therapeutic options, and stress the need for multidisciplinary management of these cases.


Sujet(s)
Immunosuppresseurs/effets indésirables , Transplantation pulmonaire , Tumeurs primitives multiples/diagnostic , Panniculite/immunologie , Sarcomes/diagnostic , Tumeurs cutanées/diagnostic , Femelle , Rejet du greffon/prévention et contrôle , Humains , Inflammation , Adulte d'âge moyen , Tumeurs primitives multiples/immunologie , Tumeurs primitives multiples/anatomopathologie , Panniculite/complications , Broncho-pneumopathie chronique obstructive/étiologie , Broncho-pneumopathie chronique obstructive/chirurgie , Emphysème pulmonaire/étiologie , Emphysème pulmonaire/chirurgie , Sarcomes/immunologie , Sarcomes/anatomopathologie , Tumeurs cutanées/immunologie , Tumeurs cutanées/anatomopathologie , Déficit en alpha-1-antitrypsine/complications
19.
Am J Dermatopathol ; 38(6): 456-60, 2016 Jun.
Article de Anglais | MEDLINE | ID: mdl-27205908

RÉSUMÉ

Malignant melanoma may exhibit morphologic characteristics of nonmelanocytic cell or tissue components, a phenomenon termed divergent differentiation. Melanoma with rhabdomyosarcomatous differentiation is rare, with 6 definite cases in adults reported in the literature. The authors describe a 75-year-old man with a cutaneous lesion of the right ear initially diagnosed as malignant melanoma. Three months later, biopsy of a right cervical lymph node showed changes suggestive of rhabdomyosarcoma. Reexamination of the initial skin biopsy with muscle markers confirmed a diagnosis of malignant melanoma with rhabdomyosarcomatous differentiation. This case serves to highlight the diagnostic challenges associated with this rare subtype of melanoma.


Sujet(s)
Mélanome/anatomopathologie , Tumeurs cutanées/anatomopathologie , Sujet âgé , Marqueurs biologiques tumoraux/analyse , Différenciation cellulaire , Issue fatale , Humains , Immunohistochimie , Mâle , Rhabdomyosarcome/anatomopathologie ,
20.
J Am Acad Dermatol ; 69(4): 595-602.e1, 2013 Oct.
Article de Anglais | MEDLINE | ID: mdl-23871719

RÉSUMÉ

BACKGROUND: No established standard of care exists for aggressive cutaneous squamous cell carcinoma (CSCC). OBJECTIVE: We sought to establish an aggressive CSCC management protocol by reviewing high-risk CSCC (HCSCC) and very high-risk CSCC (VCSCC) cases at our institution. METHODS: This was a retrospective review of all CSCC cases treated at our institution. RESULTS: A total of 27 patients were identified of 1591 cases treated between 2000 and 2011. Four patients with HCSCC received surgery alone and 1 received surgery and radiation. All remain disease free (median follow-up 5 years). Among patients with VCSCC, 4 received surgery alone: 1 (25%) showing a complete response and 3 (75%) showing disease progression. Eleven received surgery and radiation: 4 (36.4%) with complete response (median follow-up 3 years) and 7 (63.6%) with disease progression (median time to recurrence 6 months). Six received surgery and cetuximab: 3 (50%) had a complete response (median follow-up 3 years), 2 (33%) had disease progression, and 1 (14%) could not be assessed because of inability to tolerate infusions. One patient received surgery, cetuximab, and radiation, and remains disease-free after 4 years. LIMITATIONS: Lack of randomization, blinding, a true control arm, or standardization of treatment protocols are limitations. CONCLUSIONS: Patients with very HCSCC may have improved outcomes with surgery and adjuvant cetuximab.


Sujet(s)
Carcinome épidermoïde/anatomopathologie , Carcinome épidermoïde/thérapie , Chirurgie de Mohs , Tumeurs cutanées/anatomopathologie , Tumeurs cutanées/thérapie , Adulte , Sujet âgé , Anticorps monoclonaux humanisés/usage thérapeutique , Ponction-biopsie à l'aiguille , Carcinome épidermoïde/mortalité , Cétuximab , Traitement médicamenteux adjuvant , Études de cohortes , Association thérapeutique , Survie sans rechute , Femelle , Études de suivi , Tumeurs de la tête et du cou/mortalité , Tumeurs de la tête et du cou/anatomopathologie , Tumeurs de la tête et du cou/thérapie , Humains , Immunohistochimie , Modèles logistiques , Mâle , Adulte d'âge moyen , Invasion tumorale/anatomopathologie , Stadification tumorale , Radiothérapie adjuvante , Études rétrospectives , Appréciation des risques , Tumeurs cutanées/mortalité , Analyse de survie , Facteurs temps , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE